Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 8/20 | 0.51 |
| ▸ | ANO2 | Q9NQ90 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6991198 | 0.87 | MAPT (0.59) | MAPTTHRBSMN1; SMN2MEN1NPC1 | |
| SCHEMBL6995066 | 0.83 | MAPT (0.55) | MAPTTHRBMEN1NPC1RAB9A | |
| SCHEMBL6992026 | 0.83 | MAPT (0.67) | MAPTTHRBSMN1; SMN2MEN1NPC1 | |
| SCHEMBL6998812 | 0.76 | MAPT (0.55) | MAPTTHRBMEN1NPC1RAB9A | |
| SCHEMBL7000741 | 0.76 | MAPT (0.67) | MAPTTHRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6997036 | 0.73 | NPC1 (0.47) | MAPTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL21853900 | 0.72 | ANO1 (0.76) | MAPTSMN1; SMN2MEN1KMT2AANO1 | |
| SCHEMBL21853988 | 0.70 | TP53 (0.79) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL7217418 | 0.70 | CYP1A2 (0.68) | MAPTTHRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6993898 | 0.69 | PTPN1 (0.54) | MAPTTHRBMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1016664-B1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6455521-B1 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1016664-A1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | ACIN1, ACHE, TPMT | MAPT 15/4885THRB 1692/4885SMN1; SMN2 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.